Combined therapy with low‐dose omalizumab and intravenous immunoglobulin for severe atopic dermatitis. Report of four cases

Toledo, Fernando; Silvestre, Juan Francisco; Muñoz, Carlos

doi:10.1111/j.1468-3083.2011.04326.x

Cited by 27 publications

(22 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A case series has reported benefits with omalizumab plus intravenous immunoglobulin for severe AD [88]. In 2014, Hotze et al conducted a prospective 28-week open-label trial on 20 adults with moderate-to-severe AD to evaluate the efficacy of omalizumab in AD and to identify markers associated with treatment response.…”

Section: Skin Diseasesmentioning

confidence: 96%

Off-Label Uses of Omalizumab

El-Qutob¹

2015

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

The off-label use of medicines is a common and extensive clinical practice. Omalizumab has been licensed for use in severe allergic asthma and chronic urticaria. Omalizumab dosing was based on body weight and baseline serum IgE concentration. All patients are required to have a baseline IgE between 30 and 700 IU/ml and body weight not more than 150 kg. The use of off-label drugs may lead to several problems including adverse effects and an increased risk/benefit balance. In this article, there are summarized off-label uses of omalizumab in the last recent years in diseases in which IgE maybe or certainly has a corner role such as allergic rhinitis, allergic bronchopulmonary aspergillosis, anaphylaxis, keratoconjunctivitis, food allergy, drug allergy, urticaria, angioedema, non-atopic asthma, atopic dermatitis, nasal polyps, Churg-Strauss syndrome, eosinophilic otitis media, chronic rhinosinusitis, bullous pemphigoid, contact dermatitis, and others. Use in pregnancy asthmatic women and pre-co-administration with specific immunotherapy will also be revised.

show abstract

Section: Skin Diseasesmentioning

confidence: 96%

Off-Label Uses of Omalizumab

El-Qutob¹

2015

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

show abstract

“…In a recent study, AE patients with wild-type filaggrin status responded to omalizumab treatment [89]. Interestingly, in patient with severe AE, treatment with omalizumab combined with IVIG [90] or combined with rituximab [91] resulted in drastic clinical improvement.…”

Section: Anti-ige Treatmentmentioning

confidence: 99%

“…Because so many cytokines are involved in orchestrating and perpetuating inflammation in AE, development of a drug that inhibits the synthesis of multiple T H 2 cytokines or chemokines may be a promising strategy to treat patients with severe AE. Thus, an approach may be the development of broadspectrum cytokine inhibitors or combination of different monoclonal antibodies as shown in limited case [90,91]. Thus, these 'broad spectrum' biologicals might be a novel approach to treat severe atopic diseases and further immunomodulating agents might even be developed for topical use in future.…”

Section: Expert Opinionmentioning

confidence: 99%

What is new in atopic dermatitis/eczema?

Plötz

Wiesender

Todorova³

et al. 2014

Expert Opinion on Emerging Drugs

View full text Add to dashboard Cite

Basic therapy consists of hydrating topical treatment and avoidance of specific and unspecific provocation factors. For acute eczematous skin lesions, anti-inflammatory treatment consists mainly of topical glucocorticoids and topical calcineurin inhibitors. Microbial colonization and superinfection may induce skin exacerbation, which can be treated by either topical or systemic antimicrobial treatment. Systemic anti-inflammatory therapy is limited to severe cases and consists of systemic steroids, cyclosporine A or mycophenolate mofetil. Novel anti-inflammatory concepts that go beyond corticosteroids are in the early phases of development. There are targeted therapeutic approaches, such as cytokine and chemokine modulators, and it remains to be investigated how effective they will be and what side effects they may carry. Existing treatment modalities such as barrier repair therapy, topical immunosuppressive agents, antiseptic treatment as well as systemic treatment options are discussed.

show abstract

“…1) [1,2]. In many cases, urticaria may be accompanied by other manifestations, including angioedema and dermatographism.…”

Section: Introductionmentioning

confidence: 97%

Intravenous Immunoglobulin as a Potential Therapy for Refractory Urticaria - A Review

Watkins¹,

Peiris²,

Saleh³

et al. 2012

IADT

View full text Add to dashboard Cite

Urticaria can be a chronic and debilitating affliction and is a relatively common disorder affecting between 10- 20% of the population. Common causes include reactions to medication, food allergen, physical stimuli and venoms. Urticaria can be acute or chronic. Chronic urticaria lasts for more than 6 weeks and is commonly difficult to treat. The use of immunosuppressive agents for this disorder when antihistamines fail can result in significant morbidity. Recent advances in the pathogenesis, etiology, diagnosis and management of chronic urticaria have led to new paradigms in treatment of this disorder. Cyclosporine is often the most effective but has some unique adverse effects that may prevent it from being used in some patients. The use of intravenous immunoglobulin (IVIG) has proven effective in a variety of reports and we will review the mechanisms likely involved in the successful control of urticarial symptoms by immunomodulating therapy using IVIG. In this review, we will discuss mechanisms and pathogenesis of urticaria and the specific role of intravenous immunoglobulin (IVIG) in this disorder, especially in refractory or steroid-dependent cases.

show abstract

Combined therapy with low‐dose omalizumab and intravenous immunoglobulin for severe atopic dermatitis. Report of four cases

Cited by 27 publications

References 11 publications

Off-Label Uses of Omalizumab

Off-Label Uses of Omalizumab

What is new in atopic dermatitis/eczema?

Intravenous Immunoglobulin as a Potential Therapy for Refractory Urticaria - A Review

Contact Info

Product

Resources

About